FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, in particular to the manufacture of a drug for the treatment of ovarian cancer. To do this, an inhibitor of poly(adenosine diphosphatribose)polymerase is used in a combination with VEGFR inhibitor, and VEGFR inhibitor is VEGFR-2 inhibitor, wherein the inhibitor of poly(adenosine diphosphatribose)polymerase is a compound of the formula (B) or its pharmaceutically acceptable salt, and VEGFR-2 inhibitor is a compound of the formula (I) or its pharmaceutically acceptable salt.
EFFECT: invention provides for a synergetic effect of a combination in the treatment of recurrent ovarian cancer sensitive to platinum preparations.
16 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
| APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS | 2019 |
|
RU2783846C1 |
| CHIAURANIB FOR TREATING SMALL CELL LUNG CANCER | 2020 |
|
RU2784869C1 |
| METHOD INCLUDING FIXED FRACTIONAL DOSING OF CEDIRANIB | 2017 |
|
RU2740849C2 |
| METHODS AND COMBINED THERAPEUTIC PRODUCT FOR THE TREATMENT OF BILE DUCTS CANCER | 2019 |
|
RU2793543C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | 2021 |
|
RU2821030C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
